Alkem Labs sees Rs 930 crore block deal as promoter family entities pare stake; Goldman, Morgan Stanley among key buyers

A large block deal in Alkem Labs, driven by promoter stake sale to institutional investors, signals confidence in the company's prospects and the pharmaceutical sector. This could lead to increased trading volume and potential price appreciation for investors following the company.